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We have investigated the distribution and fatty acid preference of two acyl-CoA transferase activities in 
a human platelet mixed membrane fraction and in well-characterised surface and intracellular membrane 
subfractions prepared from it by high-voltage free-flow electrophoresis. One transferase inserts long-chain 
unsaturated fatty acids into I-acyllysophosphatidylcholine (I-acyl-LPC) and the other into lyso-platelet-ac- 
tivating factor (LPAF). Both transferase activities were approx. 4-fold enriched in the intracellular mem- 
branes with respect o their specific activities in the mixed membranes. The surface membrane activities were 
correspondingly depleted. Using I-acyl-LPC as the acceptor, all the intracellular membrane preparations 
showed transferase preference for the CoA ester of 8,11,14-eicosatrienoic a id. In contrast when LPAF was 
the acceptor the CoA esters of linoleic and arachidonic acid were the preferred donors. 
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1. INTRODUCTION 
The choline-containing phosphoglycerides of 
platelets are one source of the free arachidonic acid 
(AA) used for the biosynthesis of prostaglandin 
endoperoxides and thromboxanes [l-2]. Diacyl- 
phosphatidylcholine (diacyl-PC) is presumed to be 
the predominant PC species from which AA can be 
liberated and the total amount of this fatty acid 
esterified in diacyl-PC may influence the size of the 
free AA pool that stimulated platelets can pro- 
duce. It has been recently demonstrated that 
alkylacyl-PC is a minor but significant component 
of the total choline-containing phosphoglycerides 
in cell membranes [3,4] and since it is enriched in 
AA [4] it may also contribute as a precursor for 
prostanoid synthesis. Alkylacyl-PC is, however, 
both a precursor and a metabolite of platelet- 
activating factor (PAF) since not only can it be 
+ To whom correspondence should be addressed 
converted to PAF via a deacylation-acetylation 
reaction [4-61, but both alkylacyl-PC and lyso- 
PAF (LPAF) are formed when PAF is incubated 
with human platelets [7]. 
The fatty-acyl-CoA transferases are known to 
insert fatty acids into lysophospholipids of other 
cells via the remodelling of Land’s pathway [8] and 
this pathway is probably a major route for the in- 
corporation of highly unsaturated fatty acids into 
platelet phospholipids [9]. Moreover, this process, 
in combination with the known selectivity for AA 
of the fatty-acyl-CoA synthetase [lo], the en- 
zyme(s) which produces the fatty acyl donors for 
the transferases, could be important in regulating 
the distribution of AA in platelet phospholipids. In 
previous reports, using a crude mixed membrane 
fraction prepared from sonicated platelets, two 
fatty-acyl-CoA transferase activities were iden- 
tified [9,11]. These enzyme activities insert un- 
saturated fatty acids into 1-acyl-LPC or LPAF giv- 
ing respectively diacyl-PC and alkylacyl-PC. 
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Here, we have used highly purified human 
platelet surface and intracellular membranes to in- 
vestigate the distribution and activities of the fatty- 
acyl-CoA transferases which produce diacyl-PC 
and alkylacyl-PC from 1-acyl-LPC and LPAF, 
respectively. Additionally, some evidence is 
presented for the predominant localisation of 
alkylacyl-PC in the intracellular membranes and 
this is in general agreement with the subcellular 
distribution of its fatty-acyl-CoA transferase ac- 
tivity reported here. 
2. EXPERIMENTAL 
Unsaturated fatty acyl chlorides were obtained 
from NuChek Prep (Elysian, MN). Avanti 
Biochemicals (Birmingham, AL) supplied semisyn- 
thetic LPAF (prepared from beef heart PC) and 
I-acyl-LPC (prepared from egg PC). This com- 
mercial LPAF has previously been shown to be 
free of any detectabie contamination with l-acyl- 
LPC [l 11. Both LPAF and 1-acyl-LPC gave a 
single spot on TLC (chloroform : methanol :acetic 
acid : water, 100 :65 : 14 : 6, by vol.). Coenzyme A, 
lithium salt (Chromatopure), was obtained from 
P-L Biochemicals (Milwaukee, WI) and DTNB 
was supplied by Sigma. The [choline-meth- 
yl-3H]dipalmitoyl-PC and [l ,2-alkyl-3H]PAF were 
purchased from New England Nuclear (Boston, 
MA). 
2.1. Preparation of platelet membrane fractions 
The procedures for preparation of the mixed 
membrane fraction and for the isolation of human 
platelet surface and intracellular membranes were 
essentially as reported in [12] with only minor 
modifications. Briefly, human platelets were 
isolated by differential centrifugation from fresh 
whole blood or buffy coat residues upplied by the 
Blood Transfusion Service Laboratories at 
Tooting, London. Generally, processing of the 
buffy coat in the laboratory began within 2-3 h of 
donation. After washing, the platelets were ex- 
posed to neuraminidase (Sigma grade X, 
0.05 U/ml) for 20 min to remove sialic acid and 
lower the surface membrane electronegativity. 
They were then washed, resuspended in buffer 
(10 mM Hepes, 0.34 M sorbitol, pH 7.2) and 
sonicated. After a low-speed centrifugation to 
remove unbroken cells and large debris, the 
sonicate was applied to the surface of a 1 .O-3.5 M 
sorbitol density gradient and centrifuged for 
90 min at 42000 x g. The mixed membrane frac- 
tion, which was well separated from the higher 
density granular components, was removed from 
the low-density region of the gradient and washed 
by centrifugation (90 min at 100000 x g). This 
membrane fraction, which contained both surface 
and intracellular elements, was applied to the 
chamber of a VAP-5 free-flow electrophoresis ap- 
paratus (Bender-Hobein, Munich) operating at 
140 mA, 100 V/cm and 6°C. The mixed mem- 
brane fraction separated into 2 discrete subfrac- 
tions consisting of surface and intracellular mem- 
brane vesicles with the former represented by the 
least electronegative peak. After profiling this 
separation by protein assay, these 2 major mem- 
brane subfractions were pooled across the peaks, 
centrifuged and resuspended to wash and concen- 
trate for analytical and enzyme determinations. 
2.2. Fatty-acyl-CoA transferase assay 
The unsaturated fatty acyl-CoA esters were 
prepared and characterized as in [9]. They were 
stored in 10 mM citrate-phosphate buffer, pH 5.9, 
containing sodium ascorbate, 2.5-5.0 mM final 
concentration, to prevent oxidation as described 
[91. 
The acyl-CoA : 1 -acyl-sn-glycero-3-phosphocho- 
line acyltransferase and acyl-CoA : 1 -alkyl-sn-gly- 
cero-3-phosphocholine acyltransferase activities of 
the membrane fractions were measured at room 
temperature using the spectrophotometric assay 
described by Lands and Hart [ 131. All substrates 
were used at saturating concentrations. The assay 
mixtures consisted of 0.8 ml of 85 mM phosphate 
buffer, pH 7.0, in the case of I-acyl-LPC or pH 
7.5 in the case of LPAF; 0.1 ml of 3.3 mM DTNB; 
0.1 ml of 1.0 mM I-acyl-LPC or 1.5 mM LPAF; 
and 1- 10 ~1 of the fatty acyl-CoA solution of final 
concentration 63.6 + 0.63 and 20.4 + 0.55 PM for 
I-acyl-LPC and LPAF, respectively. Reference 
cuvettes were exactly the same except that 0.1 ml 
water was substituted for the lysophospholipid 
solutions. The membrane preparation (6-30 ~1, 
containing 23.6-133.5 fig membrane protein) was 
added simultaneously to the test and reference 
cuvettes to initiate the reaction. Initial rates were 
calculated from a continuous recording of the en- 
zyme activity. 
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3. RESULTS 
All enzyme activities have been expressed as in- 
itial rates determined from continuous recordings 
of activity measured under conditions of substrate 
saturation (predetermined for each donor/accep- 
tor system). Table 1 shows the activities (mean + 
SD for 4 preparations) for the enzyme which 
transfers fatty acyl groups to I-acyl-LPC in the 
mixed membrane fractions and in the surface and 
intracellular membrane subfractions derived from 
them by the free-flow electrophoresis procedure. It 
can be seen that for all the fatty acyl groups 
studied the specific activities of the transferase, 
associated with the intracellular membranes were 
-4-fold higher than those in the mixed membrane 
fraction from which the intracellular membrane 
was derived. In contrast, the surface membrane ac- 
tivities all showed depletion with respect o the cor- 
responding mixed membrane activity. When the 
specific activities for the different donor CoA 
esters are compared, it can be seen that for this 
lysophospholipid acceptor, 1-acyl-LPC, the CoA 
ester of 8,ll ,lCeicosatrienoic acid was the pre- 
Table 1 
Acyl-CoA-transferase activities in human platelet membrane fractions: acceptor -
1 -acyllysophosphatidylcholine 
Fatty acyl-CoA Acyl-CoA transferase activity (nmol . min-’ . mg-‘) 
Mixed 
membranes 
(MM) 
Surface 
membranes 
(SM) 
Intracellular 
membranes 
(IM) 
Activity 
ratio 
IM/MM 
18:l (9) 28.4 f 6.0 9.5 + 2.8 113.6 f 33.5 4.06 
18:2 (9,12) 29.0 f 5.3 9.8 f 2.6 114.9 + 22.6 3.96 
20:3 (8,11,14) 56.2 + 10.1 18.3 + 4.3 221.6 + 43.0 3.94 
20:4 (5,8,11,14) 28.4 + 5.4 11.6 + 2.5 115.5 f 22.6 4.07 
mean activity ratio 4.00 
The spectrophotometric assay is described in section 2. All activities are means f SD 
for 4 different platelet preparations. The double bond positions for the CoA ester fatty 
acids are in parentheses 
Table 2 
Acyl-CoA-transferase activities in human platelet membrane fractions: acceptor - 
lyso-platelet-activating factor 
Fatty acyl-CoA 
18:l (9) 
18 -2 (9,12) 
20:3 (8,11,14) 
20:4 (5,8,11,14) 
Acyl-CoA transferase activity (nmol . min-’ . mg-‘) 
Mixed Surface Intracellular Activity 
membranes membranes membranes ratio 
(MM) (SM) (TM) IM/MM 
0.5 f 0.8 1.0 f 1.1 2.2 -t 1.3 4.40 
5.2 f 1.2 2.7 f 2.1 20.6 f 4.1 3.96 
2.6 + 0.9 1.6 f 1.0 10.9 XL 2.8 4.19 
4.8 f 0.5 2.3 f 0.9 21.6 f 6.0 4.50 
mean activity ratio 4.26 
The spectrophotometric assay is described in section 2. All activities are means f SD 
for 4 different platelet preparations. The double bond positions for the CoA ester fatty 
acids are in parentheses 
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ferred donor in all membrane fractions, with 
oleate, linoleate and arachidonate, all being 
transferred at significantly lower rates. 
Table 2 shows the activities for LPAF as the ac- 
ceptor and again the intracellular membrane 
transferase activities for all donor CoA esters were 
over 4-fold enriched with respect o activities in the 
mixed membrane fractions. The surface membrane 
activities showed depletion with respect to the 
mixed membranes. However, with LPAF the CoA 
esters of linoleic and arachidonic acids were the 
preferred fatty acyl group donors in all 3 mem- 
brane fractions from all the platelet preparations 
studied. 
The preliminary determinations of endogenous 
alkylacyl-PC in the membrane fractions were 
made. These were carried out by extraction of the 
phospholipids, isolation of the choline-containing 
phosphoglycerides, conversion of any alkylacyl- 
PC present into PAF. by alkaline hydrolysis follow- 
ed by acetylation and assay by aggregometry exact- 
ly as described earlier [ 1 I]. The intracellular mem- 
brane fractions, in which the transferase enzymes 
were predominantly localised, contained 6.2 and 
7.1 nmol-mg-’ protein (n = 2) of alkylacyl-PC, 
whereas its concentration in the surface membrane 
fraction was only 1.9 and 3.5 nmol . mg-’ protein 
(n = 2). 
4. DISCUSSION 
Here, we have demonstrated that 2 fatty-acyl- 
CoA transferase activities, previously characteriz- 
ed in a mixed population of human platelet mem- 
branes as acyl-CoA : I-acyl-sn-glycero-3-phospho- 
choline acyltransferase [9] and acyl-CoA: l-alkyl- 
sn-glycero-3-phosphocholine acyltransferase [l l] 
are substantially enriched in a highly purified in- 
tracellular membrane fraction. Additionally, the 
rank order of fatty acyl group selectivity appears 
to be maintained for each lysophospholipid accep- 
tor in each membrane fraction regardless of the 
differences in specific activity between the dif- 
ferent membrane fractions. In the case of l-acyl- 
LPC, there is no clear preference observed in the 
rate of transfer of oleate, linoleate, or arachi- 
donate, but a significant preference was shown for 
the CoA ester of 8,11,14-eicosatrienoate. How- 
ever, when LPAF is the acceptor, the CoA esters 
of arachidonic and linoleic acids were the preferred 
donors. 
The intracellular membrane fraction has been 
earlier shown to contain a higher percentage of 
choline-containing phosphoglycerides than the sur- 
face membrane fraction [15]. Included in this 
group of phospholipids, diacyl-PC is believed to be 
the most important source of the AA liberated by 
phospholipase A2 in stimulated platelets. Our 
preliminary data show that another choline- 
containing phosphoglyceride, alkylacyl-PC, the 
product of the acylation of LPAF with un- 
saturated fatty acids, is also enriched in the in- 
tracellular membrane fraction. Alkylacyl-PC is the 
probable precursor of PAF as well as a metabolite 
of PAF in platelets [7,14] and the selectivity of the 
fatty-acyl-CoA transferase for arachidonate sug- 
gests that this alkylacyl-PC could be enriched in 
AA relative to other unsaturated fatty acids. This 
would be in agreement with the recent findings that 
over 40% of the fatty acid at m-2 of alkylacyl-PC 
is arachidonate [4,14]. 
The selectivity of the fatty-acyl-CoA trans- 
ferases for unsaturated fatty acyl groups, when 
1-acyl-LPC and LPAF are acceptors, strengthens 
the concept that the remodelling pathway is an im- 
portant one for the incorporation of unsaturated 
fatty acids into platelet phospholipids [9]. Sup- 
porting evidence for this has been provided by 
Neufeld and Majerus [la] who estimated the rate 
of turnover of AA in ‘resting’ platelets and sug- 
gested that this may be associated with the re- 
modelling of platelet phospholipids. It is now ac- 
cepted that the fatty acid composition of mem- 
brane phospholipids is not stable, but responds 
dynamically to changes in the environment and the 
remodelling pathway is probably the major route 
by which phospholipids of platelets are labelled 
when radioactive AA is used [ 171. This remodelling 
probably also explains the finding that radioactivi- 
ty from 2-[1-r4C]arachidonyl-PC, which is ap- 
parently taken up as an intact phospholipid into 
platelets, eventually appears in phospholipid 
classes other than PC [17]. The participating en- 
zymes phospholipase A2 and the fatty-acyl-CoA 
transferase, are both enriched in the intracellular 
membranes and in earlier studies the intracellular 
membrane phospholipase A2 activity showed a 
preference for 2-[1-14C]arachidonyl-PC over other 
2-acylphosphatidylcholines [ 18,191. From our 
earlier analytical studies of these membrane sub- 
fractions prepared by free-flow electrophoresis it 
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was shown that PC and phosphatidylinositol 
(another source of free AA) were enriched in the 
intracellular membranes and moreover the percen- 
tage of AA in PC was higher in the intracellular 
membranes than in the PC of the surface mem- 
branes [15]. 
There is now a strong body of evidence sug- 
gesting that considerable metabolism of AA by 
human platelets can proceed at intracellular sites 
[20,21] and from the present findings we can now 
include acyltransferases in this list. The key role of 
the metabolites of AA in thrombosis [22] suggests 
that a successful pharmacological approach to this 
disease may require agents which can penetrate the 
surface membrane rapidly and allow selective in- 
terference with intracellular membrane processes. 
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